Articolo in rivista, 2010, ENG
Laezza C; Malfitano A; Proto MC; Esposito I; Gazzerro P; Formisano P; Pisanti S; Santoro A; Caruso MG; Bifulco M.
CNR, Inst Endocrinol & Expt Oncol, I-80131 Naples, Italy Univ Naples Federico 2, Dept Biol & Cellular, I-80131 Naples, Italy Univ Salerno, Dept Pharmaceut Sci, I-84084 Salerno, Italy Natl Inst Digest Dis, I-70013 Bari, Italy
The endocannabinoid system regulates cell proliferation in human breast cancer cells. Recently, we described that a metabolically stable anandamide analog, 2-methyl-2'-F-anandamide, by activation of CB1 receptors significantly inhibited cell proliferation of human breast cancer cell lines. In this study, we observed that the activation of the CB1 receptor, in two human mammary carcinoma cell lines, MDA-MB-231 and MCF7, caused the inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity due to a reduction of HMG-CoA reductase transcript levels. The decrease of HMG-CoA reductase activity induced the inhibition of the prenylation of proteins, in particular of the farnesylation of Ras oncogenic protein involved in cell proliferation of these cell lines. We suggest that the inhibitory effect of anandamide analog on tumor cell proliferation could be related to the inhibition of Ras farnesylation.
Endocrine-related cancer 18 , pp. 495–503
IEOS – Istituto per l'endocrinologia e l'oncologia "Gaetano Salvatore"
ID: 21321
Year: 2010
Type: Articolo in rivista
Creation: 2010-12-07 00:00:00.000
Last update: 2015-11-19 15:25:45.000
CNR authors
External IDs
CNR OAI-PMH: oai:it.cnr:prodotti:21321
ISI Web of Science (WOS): 000279341700020